Ensysce Biosciences is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the world. Through its proprietary TAAP technology Ensysce is in the process of receiving approval for an abuse-resistant yet still pain-relieving opioid. The company released 1Q2025 financial data and reminded investors that 2025 is looking to be a potentially pivotal year for ENSC.
